OncoMatch/Clinical Trials/NCT06173362
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Is NCT06173362 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Abiraterone and Darolutamide for advanced prostate adenocarcinoma.
Treatment: Abiraterone · Darolutamide · Prednisone — This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Androgens (male hormones) can cause the growth of prostate tumor cells. Abiraterone acetate lowers the amount of androgens made by the body. This may help stop the growth of prostate tumor cells that need androgen to grow. Darolutamide blocks the use of androgens by the tumor cells. Prednisone is used to lessen inflammation and lower the body's immune response. Researchers want to compare the side effects of standard of care (SOC) abiraterone and prednisone or darolutamide alone in treating patients with advanced prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage III, IV
Performance status
KARNOFSKY 50–100
Demographics
Prior therapy
Must have received: androgen deprivation therapy
Participants are encouraged to be currently treated with androgen deprivation therapy (ADT) or having undergone bilateral orchiectomy
Cannot have received: abiraterone (abiraterone)
Exception: ≤ 28 days prior to initiating enrollment
Have been on either abiraterone or darolutamide for > 28 days prior to initiating enrollment
Cannot have received: darolutamide (darolutamide)
Exception: ≤ 28 days prior to initiating enrollment
Have been on either abiraterone or darolutamide for > 28 days prior to initiating enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06173362 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior abiraterone, darolutamide disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages